The European major medical regulator, European Medicines Agency (EMA), announced on Thursday adding a new rare side effect for Johnson & Johnson COVID-19 vaccine.
The agency said that the new side effect is a type of spinal inflammation known as transverse myelitis.
In the same context, the agency referred that this serious rare side effect was detected in the early trials of developing another vaccine that follows the same technology which is AstraZeneca.
Moreover, it gave new updates on the safety of all Coronavirus vaccine shots, pointing out a rare blood condition known as Capillary Leak Syndrome (CLS) linked with the Moderna vaccine.
It is worthy to mention that EMA announced on Wednesday that it started reviewing the Moderna COVID-19 vaccine for children aged from 6 to 11 years old.
The leading drug manufacturing corporation said that it officially applied to EMA to have authorization for their COVID-19 vaccine to be used for younger people.
Regarding the duration of the process, the European medical regulator said in a statement: “The current timeline for evaluation foresees an opinion in approximately two months unless supplementary information or analysis is needed.”
It added: “This is a shortened timetable compared to similar types of reviews outside of a pandemic.”
Follow the latest news on Google News
